Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

about

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

Item

http://www.wikidata.org/entity/Q47137994

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@en

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@nl

type

Item

label

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@en

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@nl

prefLabel

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@en

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@nl

P1476

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus.

@en

P2860

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond

Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.

Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.

A Review on the Relationship between SGLT2 Inhibitors and Cancer.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

P304

e1751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.7759/CUREUS.1751

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fatima Saleem

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29226041

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5716679

http://www.w3.org/2001/XMLSchema#string